Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells

We tested the efficacy of lapatinib, a dual tyrosine kinase inhibitor which interrupts the HER2 and epidermal growth factor receptor (EGFR) pathways, in a panel of triple-negative breast cancer (TNBC) cells, and examined the drug mechanism. Lapatinib showed an anti-proliferative effect in HCC 1937,...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chun-Yu, Hu, Ming-Hung, Hsu, Chia-Jung, Huang, Chun-Teng, Wang, Duen-Shian, Tsai, Wen-Chun, Chen, Yi-Ting, Lee, Chia-Han, Chu, Pei-Yi, Hsu, Chia-Chi, Chen, Ming-Huang, Shiau, Chung-Wai, Tseng, Ling-Ming, Chen, Kuen-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891031/
https://www.ncbi.nlm.nih.gov/pubmed/26824320
http://dx.doi.org/10.18632/oncotarget.7035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891031/
https://www.ncbi.nlm.nih.gov/pubmed/26824320
http://dx.doi.org/10.18632/oncotarget.7035

Ejemplares similares